pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
tulisokibart · news · pharmadog
← back to tulisokibart
News mentioning tulisokibart
11
stories
8d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
9d
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
biospace
11d
#EADV26: Merck shows off mid-stage win for Prometheus drug in skin condition
endpoints
13d
6 immunology targets to sustain a mammoth I&I market
biospace
16d
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
biospace
Sep 8, 26
Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
fiercebiotech
Aug 5, 26
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
Aug 4, 26
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
Aug 4, 26
J&J pharma leader to retire; Krystal slumps on gene therapy miss
biopharma dive
Aug 4, 26
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
fiercebiotech
Jul 29, 26
‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
fiercebiotech
